Return to search

PE-backed SSI Strategy buys Fiore Healthcare Advisors

SSI Strategy, which is backed by Amulet Capital Partners, has acquired Fiore Healthcare Advisors LLC, a pharmacovigilance consultancy.

SSI Strategy, which is backed by Amulet Capital Partners, has acquired Fiore Healthcare Advisors LLC, a pharmacovigilance consultancy. No financial terms were disclosed.


PARSIPPANY, N.J. & BOSTON–(BUSINESS WIRE)–SSI Strategy, LLC (“SSI” or the “Company”), a leading Life Sciences consultancy, announced today that they have acquired Fiore Healthcare Advisors, LLC (FHA), a leading Pharmacovigilance consultancy and long-time SSI collaborative partner. This news comes on the heels of SSI’s December 2020 growth investment from Amulet Capital Partners, LP (“Amulet”), a middle-market private equity firm focused exclusively on the Healthcare sector.

Doug Locke, CEO of SSI Strategy stated, “We are thrilled to officially welcome FHA to the SSI family. Our partnership over the years has helped us support our clients as they deliver novel therapies while remaining committed to patient safety. The FHA team will continue to contribute to and share in the Company’s long-term strategic vision.”

Avi Uttamchandani, Principal at Amulet stated, “The acquisition of FHA aligns with SSI Strategy’s growth goals and aim to expand strategic services to support Medical, Clinical and Drug Safety functions at the C-level of Life Sciences companies. We are thrilled to see the continued growth of SSI through sustained partnerships with their clients and now the addition of FHA.”

The acquisition of long-time partner FHA will expand SSI’s already strong Clinical Research and Drug Safety offerings by onboarding a team of experienced Safety Physicians and Clinical Research experts to support across the development continuum, from trial design/strategy to Medical and Safety monitoring, signal detection and management, case processing and inspection readiness. FHA’s team of medical experts will be well supported by SSI’s current medical team and business consulting staff.

FHA’s Founder Dr. Gregory Fiore stated, “We look forward to joining forces with SSI and the positive impact it will deliver for both our people and our clients. SSI and FHA share a passion for helping companies perform clinical research, drug safety and other critical drug development activities to the absolute highest standards.” FHA also brings a strong skillset in Pharmacovigilance Consulting, Clinical Research, Clinical and PV Compliance, and Data Quality.

Adam Schwartz, President of SSI Strategy said, “SSI incorporates a blended team of MDs, former Chief Medical Officers and business consultants to deliver a model we believe brings the most value to our clients. We are enthusiastic about incorporating more Safety expertise into our portfolio rounding out our offerings in Drug Safety and Pharmacovigilance.”

About SSI Strategy
SSI Strategy combines business acumen, medical, clinical and pharmacovigilance domain expertise, and operating experience to provide unparalleled support to our clients. Our staff of ex-Chief Medical Officers and former Heads of Medical Affairs, Clinical Development and Safety will work to ensure the right balance of medical and business focus to drive unparalleled outcomes for clients. SSI Strategy is headquartered in Parsippany, NJ, with offices in Boston, London, New York, and San Francisco. For more information on SSI Strategy, please visit

About Fiore Healthcare Advisors
Fiore Healthcare Advisors is a Pharmacovigilance and Clinical Research consultancy that primarily supports early and mid-stage pharmaceutical and biotechnology companies. FHA staff are experts in Pharmacovigilance and Drug Safety, Clinical Research and Data Quality. Their primary goal is to perform alongside clients as though they are the primary sponsor, rather than a service provider. Fiore Healthcare Advisors (FHA) is headquartered in Boston, MA. For more information on Fiore Healthcare Advisors, please visit